Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cytomx Thera (CTMX)

Cytomx Thera (CTMX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 68,093
  • Shares Outstanding, K 78,259
  • Annual Sales, $ 101,210 K
  • Annual Income, $ -570 K
  • EBIT $ 7 M
  • EBITDA $ 1 M
  • 60-Month Beta 1.06
  • Price/Sales 0.69
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 5.25
  • Earnings Per Share ttm 0.17
  • Most Recent Earnings $0.07 on 11/07/24
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 145.55% ( +48.73%)
  • Historical Volatility 58.49%
  • IV Percentile 43%
  • IV Rank 17.98%
  • IV High 739.39% on 04/22/24
  • IV Low 15.34% on 09/19/24
  • Put/Call Vol Ratio 0.13
  • Today's Volume 90
  • Volume Avg (30-Day) 87
  • Put/Call OI Ratio 0.31
  • Today's Open Interest 2,172
  • Open Int (30-Day) 4,428

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.22
  • Number of Estimates 5
  • High Estimate -0.01
  • Low Estimate -0.53
  • Prior Year 0.01
  • Growth Rate Est. (year over year) -2,300.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8330 +1.63%
on 11/19/24
1.1600 -27.02%
on 11/08/24
-0.3134 (-27.02%)
since 10/21/24
3-Month
0.8330 +1.63%
on 11/19/24
1.3300 -36.35%
on 09/11/24
-0.4234 (-33.34%)
since 08/21/24
52-Week
0.8330 +1.63%
on 11/19/24
5.8500 -85.53%
on 05/01/24
-0.4584 (-35.13%)
since 11/21/23

Most Recent Stories

More News
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%

Shares of Grifols GRFS lost over 8% on Tuesday after the company’s board refused to endorse Canada-based Brookfield Asset Management’s offer to acquire its outstanding share capital for €6.45 billion...

CTMX : 0.8405 (-3.40%)
CSTL : 28.78 (+1.16%)
GRFS : 8.27 (-3.84%)
SPRO : 1.1937 (-0.52%)
CytomX Therapeutics: Q3 Earnings Snapshot

CytomX Therapeutics: Q3 Earnings Snapshot

CTMX : 0.8405 (-3.40%)
CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

CTMX : 0.8405 (-3.40%)
CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

CTMX : 0.8405 (-3.40%)
CytomX Therapeutics: Q2 Earnings Snapshot

CytomX Therapeutics: Q2 Earnings Snapshot

CTMX : 0.8405 (-3.40%)
Biotech Innovations Drive Pancreatic Cancer Treatment: Market Expected to Reach $7.4 Billion by 2032

USA News Group – Recognized as one of the most lethal cancers, researchers are striving to improve survival rates for pancreatic cancer patients by focusing on earlier detection. According to Johns Hopkins...

ONCY : 0.9815 (-1.70%)
ONC.TO : 1.39 (-0.71%)
VSTM : 3.75 (-1.06%)
CTMX : 0.8405 (-3.40%)
BNTX : 103.07 (+0.91%)
FGEN : 0.3663 (+4.66%)
Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates

/CNW/ -- USA News Group – Recognized as one of the most lethal cancers, researchers are striving to improve survival rates for pancreatic cancer patients by...

ONCY : 0.9815 (-1.70%)
VSTM : 3.75 (-1.06%)
CTMX : 0.8405 (-3.40%)
BNTX : 103.07 (+0.91%)
FGEN : 0.3663 (+4.66%)
ONC.TO : 1.39 (-0.71%)
Stocks Set to Open Higher as Investors Await Key U.S. Inflation Data and Fed Speak

June S&P 500 E-Mini futures (ESM24) are up +0.12%, and June Nasdaq 100 E-Mini futures (NQM24) are up +0.25% this morning as trading resumed after the Memorial Day holiday, with investors looking ahead...

ESM24 : 5,471.89s (-0.09%)
NQM24 : 19,747.29s (-0.08%)
DECK : 176.43 (+0.04%)
ROST : 140.52 (+0.86%)
AAPL : 226.51 (-1.09%)
WDAY : 263.59 (+1.60%)
INTU : 669.03 (+2.83%)
CRM : 336.16 (+3.21%)
DKS : 194.86 (+0.35%)
CHWY : 34.94 (+0.92%)
HPQ : 37.06 (+1.04%)
AI : 32.56 (+0.62%)
Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection

/CNW/ -- USA News Group – Hope is rising in the fight against one of the deadliest cancers in the world, as a new study recently claimed that a blood test can...

ONCY : 0.9815 (-1.70%)
CADL : 4.00 (+0.50%)
ABVC : 0.5500 (-3.07%)
CTMX : 0.8405 (-3.40%)
AMGN : 285.42 (-0.85%)
ONC.TO : 1.39 (-0.71%)
Biotech Innovations Drive Hope in Global Fight Against Pancreatic Cancer

USA News Group – Hope is rising in the fight against one of the deadliest cancers in the world, as a new study recently claimed that a blood test can accurately detect early-stage pancreatic cancer with...

ONCY : 0.9815 (-1.70%)
ONC.TO : 1.39 (-0.71%)
CADL : 4.00 (+0.50%)
ABVC : 0.5500 (-3.07%)
CTMX : 0.8405 (-3.40%)
AMGN : 285.42 (-0.85%)

Business Summary

CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered...

See More

Key Turning Points

3rd Resistance Point 0.9783
2nd Resistance Point 0.9492
1st Resistance Point 0.9096
Last Price 0.8405
1st Support Level 0.8409
2nd Support Level 0.8118
3rd Support Level 0.7722

See More

52-Week High 5.8500
Fibonacci 61.8% 3.9335
Fibonacci 50% 3.3415
Fibonacci 38.2% 2.7495
Last Price 0.8405
52-Week Low 0.8330

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar